Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Retatrutide vs Tirzepatide: A Simple Research Comparison

Retatrutide vs Tirzepatide: A Simple Research Comparison

Jun 11, 2026 4 min GLP-1 / Metabolic
TL;DR
Tirzepatide targets two hormones (GIP and GLP-1) and has extensive phase 3 trial data for weight loss and type 2 diabetes. Retatrutide targets three hormones (GIP, GLP-1, and glucagon) and showed striking early weight-loss results in a phase 2 trial. Both are research peptides with distinct dosing schedules — understanding those differences helps you read the science more clearly.

Two Peptides, One Big Question

You've probably seen both names pop up in weight-loss research. Tirzepatide has been studied in large, late-stage clinical trials. Retatrutide is the newer one — still in earlier research stages but already turning heads. So what's the actual difference? Let's keep it simple.

What Is Tirzepatide?

Tirzepatide is a synthetic peptide that mimics two gut hormones at once. Those hormones are GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both hormones tell your body to release insulin after eating and help signal fullness. Hitting two receptors at once is why researchers call it a dual agonist. "Agonist" just means it activates a receptor — like pressing a button.

In the SURPASS-1 phase 3 trial, tirzepatide was studied at doses of 5 mg, 10 mg, and 15 mg once weekly in adults with type 2 diabetes.[4] A head-to-head phase 3b trial (SURMOUNT-5) later compared tirzepatide directly to semaglutide in people with obesity but without diabetes. At 72 weeks, tirzepatide produced a mean weight loss of 20.2% versus 13.7% for semaglutide.[3] A large real-world study also found tirzepatide users were significantly more likely to reach 5%, 10%, and 15% weight-loss thresholds compared to semaglutide users.[1]

What Is Retatrutide?

Retatrutide takes things one step further. It targets three hormone receptors: GIP, GLP-1, and glucagon. That makes it a triple agonist. Glucagon is usually known for raising blood sugar, but activating the glucagon receptor in this controlled way appears to boost calorie burning. Think of it as adding a third lever.

A 2023 phase 2 trial published in the New England Journal of Medicine tested retatrutide at doses from 1 mg up to 12 mg once weekly over 48 weeks. The results were notable: participants on the 12 mg dose lost a mean of 24.2% of their body weight. At that dose, 100% of participants lost at least 5% of body weight, and 83% lost at least 15%.[2] However, this is still phase 2 data — meaning a smaller, earlier study designed mainly to check safety and find the right dose range.

Quick Comparison

  • Receptors targeted: Tirzepatide = GIP + GLP-1 (dual) | Retatrutide = GIP + GLP-1 + glucagon (triple)
  • Research stage: Tirzepatide = phase 3 (more data) | Retatrutide = phase 2 (earlier data)[2][4]
  • Dosing range studied: Tirzepatide = 5–15 mg weekly[4] | Retatrutide = 1–12 mg weekly[2]
  • Weight loss seen in trials: Tirzepatide up to ~20% at 72 weeks[3] | Retatrutide up to ~24% at 48 weeks[2]
  • Common side effects noted: Both showed mostly mild to moderate gastrointestinal effects (nausea, vomiting) in trials[2][5]
  • Head-to-head vs semaglutide: Tirzepatide has direct comparison data[1][3] | Retatrutide does not yet

Why Do Research Doses Matter?

Dosing in research trials is carefully designed. Scientists usually start low and go up slowly — this is called titration. For retatrutide, the phase 2 trial tested starting doses of 2 mg versus 4 mg. The lower starting dose helped reduce stomach side effects.[2] For tirzepatide, trials used a similar step-up approach, beginning at 2.5 mg before reaching the 5–15 mg target doses.[4]

Understanding these titration schedules is key to reading the research correctly. If you want to look up specific dosing numbers from the studies, our calculator can help you make sense of the numbers in context.

How to Choose What to Read About

Ask yourself a few questions. Are you interested in a compound with more long-term, large-scale trial data? Start with Tirzepatide. Are you curious about triple-receptor research and early-stage findings that are still unfolding? Dive into Retatrutide. Neither is better or worse for your reading — they're just at different points in the research pipeline.

Remember: all of this is for educational and research purposes only. These are not medical recommendations. Always refer to peer-reviewed sources and consult qualified professionals for any health decisions.

Sources

  1. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. — JAMA internal medicine, 2024. PMID 38976257.
  2. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. — The New England journal of medicine, 2023. PMID 37366315.
  3. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. — The New England journal of medicine, 2025. PMID 40353578.
  4. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. — Lancet (London, England), 2021. PMID 34186022.
  5. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. — Frontiers in endocrinology, 2023. PMID 37908750.
  6. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. — JAMA, 2022. PMID 35133415.
See the dosage chart — Retatrutide
An investigational triple-agonist studied for weight and metabolic outcomes.
Retatrutide

FAQ

What makes Retatrutide different from Tirzepatide?
Retatrutide activates three hormone receptors — GIP, GLP-1, and glucagon — while Tirzepatide activates two (GIP and GLP-1). That extra glucagon receptor action may increase calorie burning. In a phase 2 trial, the 12 mg retatrutide dose was linked to around 24% mean weight loss at 48 weeks, though this is earlier-stage data than what exists for tirzepatide.[2]
What doses were used in Tirzepatide research trials?
Phase 3 trials like SURPASS-1 studied tirzepatide at 5 mg, 10 mg, and 15 mg once weekly in adults with type 2 diabetes.[4] The SURMOUNT-5 trial used maximum tolerated doses of 10 mg or 15 mg weekly in people with obesity without diabetes, comparing directly against semaglutide over 72 weeks.[3]
Is Retatrutide approved for use?
As of the latest available research, retatrutide is not approved for clinical use. It completed a phase 2 trial published in 2023, which tested safety and dosing in roughly 338 adults over 48 weeks.[2] Phase 3 trials would need to follow before any regulatory approval process could begin. All content here is for research and educational purposes only.
Are the side effects of Tirzepatide and Retatrutide similar?
Both compounds showed gastrointestinal side effects — like nausea and vomiting — as the most common issues in trials. For both, these were mostly mild to moderate and tended to occur during dose escalation. Starting at a lower dose helped reduce these effects for retatrutide.[2] A meta-analysis also reviewed tirzepatide's gastrointestinal safety profile across studies.[5]
For research and educational use only. Not medical advice.